Next Article in Journal
The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia
Next Article in Special Issue
Integration of Genomic Risk Scores to Improve the Prediction of Childhood Asthma Diagnosis
Previous Article in Journal
Evidence-Based Decision Support for a Structured Care Program on Polypharmacy in Multimorbidity: A Guideline Upgrade Based on a Realist Synthesis
Previous Article in Special Issue
Vitamin D Levels in Asymptomatic Children and Adolescents with Atopy during the COVID-19 Era
Article

Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients

1
University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia
2
Biotechnical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
3
Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia
4
Department of Pulmonology, Division of Internal Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
5
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Ramesh J. Kurukulaaratchy, Hans Michael Haitchi and Reginald M. Gorczynski
J. Pers. Med. 2022, 12(1), 70; https://doi.org/10.3390/jpm12010070
Received: 29 October 2021 / Revised: 4 January 2022 / Accepted: 5 January 2022 / Published: 7 January 2022
(This article belongs to the Special Issue Personalized Understanding and Management of Asthma and Allergy)
Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction. View Full-Text
Keywords: severe asthma; anti-IL-5 biologics; induced sputum; airway eosinophilia severe asthma; anti-IL-5 biologics; induced sputum; airway eosinophilia
Show Figures

Figure 1

MDPI and ACS Style

Šokić, M.K.; Rijavec, M.; Korošec, P.; Bidovec-Stojkovič, U.; Kern, I.; Vantur, R.; Škrgat, S. Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients. J. Pers. Med. 2022, 12, 70. https://doi.org/10.3390/jpm12010070

AMA Style

Šokić MK, Rijavec M, Korošec P, Bidovec-Stojkovič U, Kern I, Vantur R, Škrgat S. Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients. Journal of Personalized Medicine. 2022; 12(1):70. https://doi.org/10.3390/jpm12010070

Chicago/Turabian Style

Šokić, Maruša K., Matija Rijavec, Peter Korošec, Urška Bidovec-Stojkovič, Izidor Kern, Romana Vantur, and Sabina Škrgat. 2022. "Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients" Journal of Personalized Medicine 12, no. 1: 70. https://doi.org/10.3390/jpm12010070

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop